Sep 18, 2019 / 08:45AM GMT
David W. Meline - Amgen Inc. - Executive VP & CFO
(technical difficulty)
We've seen good execution as we started 2019 as we drive volume-driven growth around the world in an increasingly dynamic health care environment, managing a diverse portfolio. We have representation in 6 therapeutic areas that we're investing in and commercializing. Recently announced the acquisition of Otezla to supplement our inflammation portfolio, which I'll talk about. We've also recently in July launched our first 2 biosimilars in the U.S. adding to the effort that we've already launched last year in Europe. Continue to drive investment in R&D with a rising level of investment there and some exciting opportunities developing in our pipeline. Working with the U.S. administration, advocating for patient access for affordability and for the continued support of a healthy health care sector. And then, finally, driving towards continued long-term growth for the company.
We've been going through a portfolio of transition of the business where we're now facing competition for some of our legacy products. And
Amgen Inc at Bank of America Merrill Lynch Global Healthcare Conference Transcript
Sep 18, 2019
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers